HomeCompareRVNC vs PLD

RVNC vs PLD: Dividend Comparison 2026

RVNC yields 54.79% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $5.41M in total portfolio value· pulled ahead in Year 8
10 years
RVNC
RVNC
● Live price
54.79%
Share price
$3.65
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$503.1K
Annual income
$109,600.15
Full RVNC calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — RVNC vs PLD

📍 PLD pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRVNCPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RVNC + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RVNC pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RVNC
Annual income on $10K today (after 15% tax)
$4,657.53/yr
After 10yr DRIP, annual income (after tax)
$93,160.13/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, PLD beats the other by $3,944,956.28/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RVNC + PLD for your $10,000?

RVNC: 50%PLD: 50%
100% PLD50/50100% RVNC
Portfolio after 10yr
$3.21M
Annual income
$2,430,162.66/yr
Blended yield
75.81%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

RVNC
Analyst Ratings
10
Buy
12
Hold
Consensus: Hold
Price Target
$20.78
+469.3% upside vs current
Range: $6.66 — $37.00
Altman Z
-6.3
Piotroski
3/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RVNC buys
0
PLD buys
0
No recent congressional trades found for RVNC or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRVNCPLD
Forward yield54.79%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$503.1K$5.91M
Annual income after 10y$109,600.15$4,750,725.19
Total dividends collected$409.6K$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy
Analyst price target$20.78$136.00

Year-by-year: RVNC vs PLD ($10,000, DRIP)

YearRVNC PortfolioRVNC Income/yrPLD PortfolioPLD Income/yrGap
1$16,179$5,479.45$11,241$540.96+$4.9KRVNC
2$25,597$8,285.47$13,019$991.13+$12.6KRVNC
3$39,640$12,250.87$15,801$1,870.97+$23.8KRVNC
4$60,146$17,730.52$20,609$3,701.21+$39.5KRVNC
5$89,498$25,142.31$29,919$7,867.97+$59.6KRVNC
6$130,728$34,964.84$50,631$18,617.74+$80.1KRVNC
7$187,610$47,731.17$105,528$51,352.20+$82.1KRVNC
8← crossover$264,761$64,018.61$287,364$174,449.42$22.6KPLD
9$367,729$84,434.73$1,081,760$774,280.77$714.0KPLD
10$503,070$109,600.15$5,908,209$4,750,725.19$5.41MPLD

RVNC vs PLD: Complete Analysis 2026

RVNCStock

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Full RVNC Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this RVNC vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RVNC vs SCHDRVNC vs JEPIRVNC vs ORVNC vs KORVNC vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.